Epigallocatechin-3-gallate Alleviates Cognitive Deficits in APP/PS1 Mice.

doi:10.1007/s11596-020-2142-z

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Epigallocatechin-3-gallate Alleviates Cognitive Deficits in APP/PS1 Mice.

Current medical science - 1 Feb 2020

Bao Jian, Liu Wei, Zhou Hong-Yan, Gui Yu-Ran, Yang You-Hua, Wu Meng-Juan, Xiao Yi-Fan, Shang Jin-Ting, Long Gui-Feng, Shu Xi-Ji

Abstract excerpt

Alzheimer's disease (AD) shows cognitive impairments in clinic, which is multifactorial with different etiopathogenic mechanisms such as Aβ deposition, neuroinflammation and neuronal dystrophy involved. Therefore, multi-targets drugs with neuroprotective, anti-amyloidogenic and anti-inflammatory properties will be effective in AD treatment. Epigallocatechin-3-gallate (EGCG) possesses a broad spectrum of...

Topics

Administration, Oral
Alzheimer Disease
Amyloid beta-Protein Precursor
Animals
Catechin
Cognitive Dysfunction
Cytokines
Disease Models, Animal
Gene Expression Regulation
Humans
Mice
Mice, Transgenic
Mutation
Neuroprotective Agents

Source

Open in PubMed

Identifiers

PMID: 32166661
DOI: 10.1007/s11596-020-2142-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Presenilin-1

Treatment Outcome